Quote this publication Share Print

AVASTIN (bevacizumab), monoclonal antibody

ONCOLOGY - New indication
Opinions on drugs - Posted on Jan 18 2016

Reason for request

Extension of Inclusion

No clinical added value demonstrated in treatment of the first recurrence of platinum-sensitive ovarian cancer or the recurrence of platinum-resistant ovarian cancer.

  • AVASTIN has Marketing Authorisation :

- in combination with carboplatin and gemcitabine, in the treatment of the first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer ;

in combination with paclitaxel, with topotecan or with pegylated liposomal doxorubicin, in the case of recurrence of platinum-resistant recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.

  • The addition of bevacizumab to the chemotherapy has been shown to have a moderate effect on progression-free survival, without a demonstrated increase in overall survival and quality of life but with an increase in toxicity, particularly vascular toxicity.

Clinical Benefit



Clinical Added Value

no clinical added value


Therapeutic use


Contact Us

Évaluation des médicaments